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Linezolid was approved in 2000 for treatment of gram-
positive coccal infections. We performed a case–control 
study during a hospital outbreak of linezolid-resistant en-
terococci (LRE) infections, comparing cases of LRE infec-
tion (cases) with linezolid-sensitive enterococci infections 
(controls). Nasal and perirectal swab samples were ob-
tained from all patients in a 1-day point-prevalence survey. 
We examined antimicrobial drug use and calculated the 
deﬁ  ned daily dose of linezolid per 1,000 patient-days. Fif-
teen LRE cases were identiﬁ  ed (13 Enterococcus faecalis 
and 2 E. faecium); 7 were vancomycin-resistant. Compared 
with controls, case-patients had increased in-hospital mor-
tality rates and lengths of stay. Multivariate analysis identi-
ﬁ  ed independent predictors of LRE infection: prior cultures 
positive for methicillin-resistant Staphylococcus aureus (ad-
justed odds ratio [AOR] 27), hospitalization duration before 
index culture (AOR 1.1 per day), and duration of preceding 
linezolid therapy (AOR 1.1 per day). Linezolid exposure and 
patient-to-patient transmission appear to be responsible for 
LRE infections, an important emerging hospital problem.
E
nterococci are common inhabitants of the human gas-
trointestinal tract. Although >40 enterococcus species 
exist, nosocomial infections are primarily caused by En-
terococcus faecalis and E. faecium (1). Enterococcal in-
fections are the third most common cause of nosocomial 
infection in intensive care units (ICUs), and multidrug-re-
sistant enterococcal infections have been associated with 
higher hospitalization costs and a higher number of related 
deaths (2,3).
Linezolid, 1 of the oxazolidinone class of antimicro-
bial drugs, inhibits bacterial protein synthesis by binding to 
the 50S subunit of 23S rRNA. In April 2000, linezolid was 
approved in the United States and has been heavily mar-
keted to treat methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant enterococci (VRE) in-
fections (4,5). Although more expensive than vancomycin, 
linezolid does not require testing for adequate serum drug 
concentrations or dosing adjustment for renal or hepatic 
insufﬁ  ciency (6), and it has been regarded by some health-
care providers as more effective than vancomycin in treat-
ing nosocomial pneumonia and MRSA skin and soft tissue 
infections (7–9). Most reports of linezolid-resistant entero-
cocci (LRE) have been individual cases or small case series 
(10–20) or have speciﬁ  cally described linezolid-resistant 
and vancomycin-resistant E. faecium (LRVRE) (17–22). 
We describe a large hospital outbreak of LRE infections.
Hospital A is an urban, 500-bed, adult inpatient, teach-
ing facility with surgical, transplant, and medical ICUs in 
a city of ≈850,000 persons. Community-associated MRSA 
is an important emerging pathogen in that city (23,24). At 
hospital A in 2004, 154 MRSA and 29 VRE blood cul-
ture isolates were identiﬁ   ed; compared with results for 
1997, these are increases of 428% and 725%, respectively 
(Figure 1). Linezolid became available in hospital A 
in April 2000, but it was restricted for use by infectious 
disease and critical care physicians only, some of whom 
believed it provided an advantage over vancomycin for 
treatment of MRSA, especially pulmonary MRSA (8,9). In 
February 2005, hospital A’s infection-control staff contact-
ed the Tennessee Department of Health after isolating LRE 
in the blood culture of a ventilated patient. Within a week, 
surveillance cultures identiﬁ  ed a second patient with LRE 
in the same unit. We undertook an investigation to charac-
terize the epidemiology of LRE, to determine risk factors 
1024  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 7, July 2007
Response to Emerging Infection 
Leading to Outbreak of Linezolid-
Resistant Enterococci
Marion A. Kainer,* Rose A. Devasia,*† Timothy F. Jones,* Bryan P. Simmons,‡ Kelley Melton,‡ 
Susan Chow,‡ Joyce Broyles,‡ Kelly L. Moore,* Allen S. Craig,* and William Schaffner§
*Tennessee Department of Health, Nashville, Tennessee, USA; 
†Centers for Disease Control and Prevention, Atlanta, Georgia, 
USA; ‡Methodist University Hospital, Memphis, Tennessee, USA; 
and §Vanderbilt University School of Medicine, Nashville, Tennes-
see, USA Linezolid-Resistant Enterococci
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 7, July 2007  1025 
for emergence of linezolid resistance in enterococci among 
patients previously infected or colonized with linezolid-
sensitive enterococci (LSE), and to determine outcomes 
associated with LRE infection. This investigation was ap-
proved by the institutional review board of hospital A.
Methods
Epidemiology 
Cases were identiﬁ  ed by manually reviewing hospital 
A’s microbiology susceptibility testing reports related to 
all E. faecium and E. faecalis isolates for January 2004 
through February 2005. Patients for whom a clinical iso-
late of LRE had been identiﬁ  ed during the study period 
were selected for the study. For each case, 4 randomly se-
lected hospitalized control subjects with LSE were identi-
ﬁ  ed by using hospital microbiology reports; no matching 
was performed. The index hospitalization was deﬁ  ned 
as the hospital admission during which LRE or LSE had 
been identiﬁ  ed. Trained staff performed chart reviews by 
using standard questionnaires to determine demographics, 
hospital course, immunocompromising conditions, instru-
mentation during the index hospitalization, and history of 
hospitalization and inpatient antimicrobial drug exposure 
during the 12 months preceding the index isolate. Instru-
mentation was deﬁ  ned as receipt of Foley catheteriza-
tion, chest tube, Swan-Ganz catheterization, mechanical 
ventilation, dialysis catheter, central line, arterial line, 
peripherally inserted central catheter, permanent central 
venous catheter, balloon pump, or intraabdominal or other 
surgery. Immunocompromising conditions were deﬁ  ned 
as the presence of leukemia or nonskin cancer, chronic 
renal failure, requiring dialysis, diabetes, HIV infection, 
pancreatitis, steroid use of >10 mg for >5 days, or solid 
organ or stem cell transplantation. Mortality was deﬁ  ned 
as patient death during the index hospitalization. Critical 
care areas were deﬁ  ned as the ICUs, extended postopera-
tive holding area (overﬂ  ow ICU), coronary care unit, and 
ventilator rehabilitation unit.
Specimen information for clinical isolates of E. fae-
cium, E. faecalis, S. aureus, and S. epidermidis was ob-
tained for the index hospitalization and for the preceding 
12 months. Isolates from surveillance cultures (not illness-
associated) were not included. Invasive clinical isolates 
were deﬁ  ned as isolates from any of the following sources: 
blood; bone; cerebrospinal, joint, pericardial, peritoneal, or 
pleural ﬂ  uid; surgical specimen or aspirate; or any other 
normally sterile site. Noninvasive isolates included isolates 
from sputum, urine, or wounds. We performed a subset 
analysis comparing linezolid-sensitive and vancomycin-
resistant enterococci (LSVRE) and LRVRE infections 
(case–control study II). After the initial random selection of 
controls with LSE infections, we selected additional con-
trols with LSVRE to obtain a 1:4 ratio of LRVRE-infected 
case-patients to LSVRE controls.
Point-Prevalence Survey
A 1-day point-prevalence culture survey for E. faeca-
lis, E. faecium, and S. aureus was performed in hospital 
A. On March 28, 2005, all patients hospitalized in hospital 
A were asked if they would give informed consent for the 
collection and culture of nasal and perirectal swab speci-
mens; specimens were obtained from all patients who gave 
consent. Identiﬁ  cation and antimicrobial drug susceptibili-
ties of nasal and perirectal swab specimen cultures were 
performed in hospital A’s microbiology laboratory.
Laboratory Studies
Hospital A used the Dade Microscan Walkaway 96 
(Diamond Diagnostics, Holliston, MA, USA) SI Pos Com-
bo 21 for all species identiﬁ  cation and susceptibility testing 
of gram-positive clinical isolates (25). Linezolid resistance 
was conﬁ  rmed at the Centers for Disease Control and Pre-
vention (CDC, Atlanta, GA, USA) by use of the broth-dilu-
tion method; the MIC was >16 μg/mL for all isolates tested. 
For the point-prevalence survey, hospital A microbiology 
staff plated nasal swabs specimens onto mannitol-salt agar 
plates; linezolid (30 μg) and oxacillin (1 μg) disks were 
placed in the ﬁ  rst quadrant to screen for LRSA and MRSA, 
respectively. Perirectal swabs samples were plated directly 
onto 2 bile-esculin plates, 1 of which contained 6 μg vanco-
mycin/mL to screen for VRE. A linezolid disk was placed 
on the heavy inoculum on the plate without vancomycin to 
screen for LRE.
Pulsed-ﬁ  eld gel electrophoresis (PFGE) subtyping was 
performed at the Tennessee Department of Health labora-
tory on available LRE isolates (clinical [3], surveillance 
[3], and environmental [3]) from hospital A. The PulseNet 
(CDC) standardized protocol for Listeria monocytogenes 
(26) was used for DNA preparation. Speciﬁ  c conditions 
Figure 1. No. nonduplicate blood-culture isolates of methicillin-
resistant Staphylococcus aureus (MRSA), methicillin-sensitive S. 
aureus (MSSA), and vancomycin-resistant Enterococcus faecalis 
and  E. faecium (VRE) per year, hospital A, Tennessee, 1990–
2004.RESEARCH
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adapted for this application included separate 5-h digestions 
with 100 U SmaI and 100 U ApaI restriction endonucleases 
and 18-h electrophoresis, using a CHEF Mapper (Bio-Rad 
Laboratories, Hercules, CA, USA) programmed for a mo-
lecular weight range of 25–350 kb, an initial switch time of 
2.0 s, and a ﬁ  nal switch time of 20.0 s. The PulseNet size 
standard, S. Braenderup strain H9812 (ATCC BAA-664) 
(27), was used as a size marker. PFGE ﬁ  ngerprint types 
were assigned by using the criteria of Tenover et al. (28).
By using laboratory information system data, we de-
termined the number of MRSA, methicillin-sensitive S. au-
reus, and VRE isolates cultured from hospital A inpatient 
blood samples from January 1990 through December 2004. 
Repeat isolates from the same patient within 30 days were 
excluded.
Antimicrobial Drug Usage
The deﬁ  ned daily dose (DDD) of linezolid was identi-
ﬁ  ed as 1.2 g/day. We reviewed hospital A’s pharmacy pur-
chase data for linezolid for October 2001 through February 
2005 and calculated DDD/1,000 patient-days; intravenous 
linezolid usage was analyzed by patient location (ICU or 
non-ICU). Oral linezolid use was not tracked by patient lo-
cation. Hospital A’s antimicrobial drug–prescribing restric-
tions were reviewed. Hospital A pharmacy staff conducted 
a drug-usage evaluation of linezolid for January through 
April 2005. The drug-usage evaluation included prescriber 
information, duration, and indication for linezolid; patients 
with active linezolid orders were identiﬁ  ed by concurrent 
computer printouts.
Statistical Analyses
Statistical analyses were performed by using Epi Info 
3.2.2 (CDC) and SAS v. 9.1 software (SAS Institute, Cary, 
NC, USA). Fisher exact test was used to compare categori-
cal variables; the Kruskal-Wallis test was used to compare 
continuous variables. For univariate analysis, exact meth-
ods were used for 95% conﬁ  dence intervals (CIs); for mul-
tivariate analysis, 95% Wald CIs were used. All p values 
were 2-sided. 
Results
For January 2004 through February 2005, a total of 
15 LRE cases were identiﬁ  ed (Figure 2): 2 (13%) were E. 
faecium and 13 were E. faecalis infections. Of the 15 case-
patients, 12 (80%) were black and 8 (53%) were female; 
the median age was 54 years (range 38–74 years) (online 
Appendix Table, available from www.cdc.gov/EID/con-
tent/13/1024-appT.htm). Two of the case-patients had been 
admitted to the hospital from a nursing home. For 8 of the 
15 patients, diabetes was a previous medical condition; 2 
patients had previously required dialysis, and no patients 
had been transplant recipients. Eight patients had required 
care in a critical-care area before acquiring an LRE infec-
tion. Six (40%) case-patients died.
Case–Control Study I
Sixty control patients with LSE clinical isolates were 
identiﬁ  ed. Case-patients and LSE patients did not differ 
signiﬁ  cantly by age, race, sex, immunocompromising con-
ditions, or place of origin (e.g., nursing home) (Appendix 
Table). Of the enterococcal isolates from case-patients and 
controls, 13 (87%) and 53 (88%), respectively, were E. fae-
calis. LRE isolates were more likely to have been invasive 
than LSE isolates (8 [53%] vs. 12 [20%]; odds ratio [OR] 
4.6; 95% CI 1.2–17.9).
Patients with LRE infection were more likely to die 
during their hospitalization than those with LSE infection 
(OR 9.3; 95% CI 1.8–51.2). Case-patients were hospital-
ized signiﬁ  cantly longer than controls (median 35 days 
[range 1–127] for case-patients vs. 11 days [range 1–140] 
for controls; p<0.001). Case-patients were hospitalized for 
longer periods than control patients before the index cul-
ture (20 vs. 4 days; p<0.001) and after the index culture (19 
vs. 9 days; p = 0.002).
During the preceding 12 months, LRE case-patients 
had received more cumulative days of antimicrobial drug 
treatment than LSE patients (median 58 vs. 18 days; p = 
0.003). Compared with patients with LSE infection, patients 
with LRE infection had more frequently received linezolid 
therapy during the prior 14 days (27% vs. 5%; OR 9.7; 95% 
CI 1.3–76.8). This association remained valid for receipt of 
linezolid in the prior 2, 3, and 12 months. Patients with LRE 
infection, compared with patients with LSE infection, also 
had more cumulative days of linezolid therapy (median 15 
vs. 0 days; p = 0.009); among those who had received line-
zolid, the median was 17.5 days versus 8 days (p = 0.06). 
Case-patients were less likely than control patients to have 
received vancomycin during the previous year. Apart from 
carbapenems, no other antimicrobial drugs were associated 
Figure 2. Occurrence of linezolid-resistant Enterococcus faecalis 
and E. faecium in hospital A, Tennessee, January 2004–February 
2005 (N = 15). Linezolid-Resistant Enterococci
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with LRE infection; carbapenems were usually prescribed 
together with linezolid.
Case-patients with LRE were also more likely than 
controls to have had a prior clinical isolation of MRSA 
(OR 13; 95% CI 3.0–60.4): 10 (67%) case-patients and 8 
(13%) control patients had an MRSA infection during the 
12 months before the index hospitalization. Of the 10 case-
patients with a previous MRSA infection, 5 had received 
linezolid therapy (4 after isolation of MRSA) before their 
LRE infection. 
Next, we stratiﬁ  ed prior infection with MRSA by li-
nezolid exposure. Among patients who had no linezolid 
exposure, prior MRSA infection remained strongly asso-
ciated with subsequent LRE infection (OR 23.0; 95% CI 
2.6–272.0). Conversely, when we stratiﬁ  ed linezolid expo-
sure by prior MRSA infection, the exposure was associated 
with LRE infection among those with no previous MRSA 
infection (OR 11.5; 95% CI 1.0–152.8). The association 
between prior MRSA infection and hospital stay before the 
index culture did not reach statistical signiﬁ  cance (median 
10 vs. 5 days; p = 0.2).
Case-patients with LRE infection were more likely 
than control patients to have spent time in 4 locations in 
hospital A before the index culture occurred. These loca-
tions were 3 speciﬁ  c critical care areas (a medical-surgical 
ICU, extended postoperative holding area, and ventilator 
rehabilitation unit; OR 11.0; 95% CI 2.1–61.4) and 1 ortho-
pedic/neurosurgical ward (OR undeﬁ  ned). By multivariate 
analysis, using forward logistic regression, we identiﬁ  ed 
the following as statistically signiﬁ  cant predictors of LRE 
infection: prior isolation of MRSA (adjusted OR [AOR] 
27; 95% CI 4.3–174), duration of hospitalization before in-
dex culture (AOR 1.1 per day; 95% CI 1.0–1.2), and dura-
tion of preceding linezolid therapy (AOR 1.1 per day; 95% 
CI 1.0–1.2).
Case–Control Study II
To compare patients with LRVRE and LSVRE infec-
tions, we identiﬁ  ed 7 case-patients and 28 controls. Case-
patients and controls did not differ signiﬁ  cantly by age, 
race, sex, immunocompromising conditions, instrumenta-
tion, or proportion of deaths. The length of hospitalization 
for case-patients compared with that for controls did not 
reach statistical signiﬁ  cance (42 vs. 22 days; p = 0.15). 
During the previous 12 months, the cumulative days of to-
tal antimicrobial drug therapy, and of linezolid therapy spe-
ciﬁ  cally, did not differ signiﬁ  cantly between case-patients 
with LRVRE and controls with LSVRE (median 19 vs. 6 
days; p = 0.17).
Prevalence Study
Nasal swab samples were obtained from 393 (93%) of 
the 424 hospitalized patients, and perirectal swab samples 
were obtained from 388 (92%). MRSA was isolated from 
25 (6%) of the 393 nasal swab specimen cultures; linezolid-
resistant S. aureus was not identiﬁ  ed in the cultures. VRE 
was isolated from 51 (13%) of the 388 perirectal swab 
specimens, and LRE was isolated from 4 (1%); the 4 LRE 
isolates also were resistant to vancomycin. Of the 4 patients 
with LRE, 3 were located on 2 medical-surgical wards and 
1 was located in a critical care area.
Laboratory Studies
LRE isolates from 4 case-patients (patients A–D) and 3 
environmental isolates from patient B’s room (sleep chair, 
blood-pressure cuff, and hospital bed on/off button) after 
routine cleaning were available for PFGE (Figure 3). The 
isolates from cultures of blood and rectal swab specimens 
Figure 3. Pulsed-ﬁ   eld gel electrophoresis of linezolid-resistant 
enterococci (LRE) isolates, hospital A, Tennessee. A) Digestion 
with ApaI. B) Digestion with SmaI. Isolates labeled A, B, C, and 
D refer to patients mentioned in the text. Blood, isolate from blood 
specimen culture; Rect, isolate from perirectal/rectal swab specimen 
culture; Env, environmental isolate; H9812, S. Braenderup H9812 
strain (ATCC BAA-664) (27) used as size marker. RESEARCH
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from patient A (E. faecalis) were related but distinguish-
able (1 and 2 bands different for ApaI and SmaI, respec-
tively). The environmental isolates (E. faecium) were indis-
tinguishable from patient B’s blood culture isolate. A third 
pattern was shared between patients C and D; the isolates 
of E. faecium from blood and rectal swab specimens from 
patient D were identical.
Antimicrobial Drug Use
Hospital A started using linezolid in April 2000; how-
ever, pharmacy purchase data were available only from 
October 2001 onward. DDD increased from 13/1,000 
patient-days in 2001 to 35/1,000 patient-days in 2004 
(Figure 4). Most linezolid doses were used outside criti-
cal care areas. The drug-usage evaluation identiﬁ  ed 177 
patients who received linezolid therapy (range of treatment 
duration 2–30 days). A total of 164 (93%) patients were 
prescribed linezolid by either infectious disease (118 [67% 
of 177 total patients receiving linezolid]) or critical care (46 
[26% of 177 total patients receiving linezolid]) physicians. 
Four prescribers (3 infectious disease and 1 critical care) 
accounted for 144 (81%) patients; 1 prescriber accounted 
for 64 (36%) patients. Apart from restricting prescription of 
certain antimicrobial drugs to particular specialty groups, 
no antimicrobial drug stewardship program was in place.
Infection-Control Policy Review
Patients with known VRE infection were placed on 
contact precautions. Patients with MRSA infection were 
placed on contact precautions while in critical care areas. 
Critical care–area staff performed surveillance cultures of 
urine and sputum on a weekly basis.
Discussion
We describe risk factors and outcomes associated with 
a large hospital outbreak of LRE, an emerging pathogen. 
The licensing-to-resistance time interval for linezolid was 
brief. Linezolid use increased in response to increases in 
MRSA and VRE infection in this hospital community and 
probably because of the drug’s convenience compared with 
vancomycin (e.g., good bioavailability and no requirement 
for blood-level or renal-dose adjustment). Despite being re-
stricted to use by infectious disease and critical care physi-
cians, the linezolid DDD prescribed by hospital A increased 
nearly 3-fold in 3 years; most use was outside ICUs. In 
this investigation, we found that exposure to linezolid any 
time in the preceding 12 months and the increased cumula-
tive days of linezolid use among case-patients suggest that 
antimicrobial drug pressure contributed to the emergence 
of multiple clones of LRE at hospital A. De novo resis-
tance has been documented in several instances in which 
PFGE comparisons have been made between LSE and 
LRE isolates in the same patient after exposure to linezolid 
(10,13,16). Our controls consisted of patients with clinical 
LSE isolates; use of these controls can introduce selection 
bias, potentially overestimating the OR associated with 
prior exposure to linezolid (29,30). One could hypothesize 
that linezolid protects patients against having subsequent 
culture results positive for LSE and, thus prevents patients 
from becoming members of the antimicrobial drug (line-
zolid)–susceptible control group. The duration of any such 
potential protection is unknown. However, 4 (50%) LRE 
case-patients with linezolid exposure had a nonimmediate 
exposure (>30 days before index culture) to linezolid, com-
pared with 2 (22%) LSE controls.
At hospital A, 8 (53%) of 15 patients with LRE infec-
tion had been exposed to linezolid; however, 7 (47%) had 
not been. This ﬁ  nding has been documented previously 
with nosocomial transmission of LRVRE in a transplan-
tation unit among 7 patients, of whom 6 were linezolid-
naive, and isolated from all had the same pattern on SmaI 
PFGE (17). In another study, 2 patients without linezolid 
exposure acquired LRVRE with identical PFGE patterns 
(31). A clonal outbreak was described by Dobbs et al. 
(21); only 6 (15%) of the patients had received linezolid 
before contracting LRVRE, and 17 (42.5%) were in a 
particular ICU before acquiring LRVRE. In our investi-
gation, patient C was linezolid-naive and located in the 
same critical care unit as patient D (linezolid-exposed); 
their isolates were identical on PFGE. Isolates recovered 
from patient B (linezolid-exposed) and from multiple en-
vironmental samples from patient B’s hospital room after 
routine cleaning were indistinguishable with 2 enzymes 
by PFGE, indicating possible patient-to-patient transmis-
sion through contaminated fomites or healthcare workers’ 
hands. This pattern was distinguishable from both the 
patient A pattern and patient C/D pattern. Patient-to-pa-
tient transmission is further supported by the clustering 
Figure 4. Linezolid (LZD) usage during 2001–2005 at hospital A, 
Tennessee. Use of oral and intravenous (IV) formulations is shown 
in deﬁ   ned daily doses (DDD)/1,000 patient days. Data for 2001 
and 2005 do not include all 12 months (2001 includes data from 
October through December; 2005 includes data from January 
through February). ICU, intensive care unit. Linezolid-Resistant Enterococci
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of exposures in time (January–February 2005) and space   
(3 speciﬁ  c critical care units and an orthopedic/neurosur-
gical ward).
A strong risk factor for LRE was prior MRSA infec-
tion. In 4 (27%) case-patients, linezolid was used to treat 
prior MRSA infection. However, the relationship between 
prior MRSA and LRE goes beyond this expected associa-
tion of prior MRSA and linezolid exposure. Even among 
those with no linezolid exposure, MRSA was strongly 
associated with linezolid resistance (OR 23; 95% CI 2.6–
272.0). This was conﬁ  rmed on multivariate analysis (AOR 
27). Prior MRSA infection therefore might also be a sur-
rogate marker for patient-to-patient transmission of LRE or 
increased susceptibility to nosocomial infection.
In this outbreak, patients with LRE infection expe-
rienced more illness, were hospitalized longer, and were 
more likely to die than patients with LSE infection. We 
cannot determine whether the higher number of deaths 
were attributable to LRE; additional studies are required, 
including matching of controls to case-patients on severity-
of-illness measures. In addition, our sample size and sta-
tistical power were limited by the number of cases of LRE 
and, in particular, LRVRE.
Infection-control efforts should focus on preventing 
infections and interrupting patient-to-patient transmission 
of multidrug-resistant organisms (MDROs) (32,33). Wide-
spread rise in MDROs (e.g., MRSA) likely contributes to 
increases in linezolid prescription and LRE. Tracking or re-
stricting linezolid use (e.g., for treatment of invasive VRE 
or MRSA) might reduce antimicrobial drug pressure and 
slow down emergence of LRE, which is critical because 
only a limited number of antimicrobial drugs are available 
to treat resistant gram-positive infections. Recently pub-
lished guidelines (34) recommend use of additional inter-
ventions, such as active surveillance cultures and contact 
precautions, if either of the following 2 conditions is met: 
“1) the incidence or prevalence of MDROs are not decreas-
ing despite the use of routine control measures; or 2) the ﬁ  rst 
case or outbreak of an epidemiologically important MDRO 
(e.g., VRE, MRSA) is identiﬁ  ed within a healthcare facility 
or unit. Facilities should continue to monitor the incidence 
of target MDRO infection and colonization; if rates do not 
decrease, implement additional interventions as needed to 
reduce MDRO transmission.” However, some hospitals 
might not implement active surveillance cultures because 
of concerns about potential delays in discharging colonized 
patients to nursing homes. Other obstacles are logistic (e.g., 
ensuring compliance rates >90% for surveillance cultures) 
and ﬁ  nancial (e.g., patients cannot be charged for surveil-
lance cultures, or insufﬁ  cient infection-control resources 
might exist). These concerns and obstacles should be ad-
dressed; otherwise, the response to 1 emerging resistant 
infection will breed another emerging infection.
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